Présentation de l'entreprise
Alector, Inc. operates as a clinical-stage biotechnology firm dedicated to developing therapeutic interventions designed to counteract the progression of neurodegeneration within the United States market. The company functions within the broader healthcare sector, specifically focusing on the specialized industry of biotechnology where research and development are central to its operational model. Its current scale is defined by a market capitalization of $267.08M, an annual revenue stream of $21.05M, and an organizational structure employing 103 individuals. These valuation and revenue figures indicate that the company maintains a relatively small market presence, which is characteristic of early-stage biotechnology entities that prioritize pipeline development over immediate profitability, thereby limiting its market share in the competitive pharmaceutical landscape.
Santé financière
The company reported a revenue of $21.05M for the trailing twelve months, while simultaneously recording a net income of $-142,928,992 and an EBITDA of $-147,367,008. The substantial disparity between the positive revenue figure and the deeply negative net income reveals a cost structure heavily weighted toward research and development expenses, operational overheads, and likely significant one-time restructuring or acquisition costs that consume the entirety of operating cash inflows. Free cash flow stands at $-114,339,128, indicating that the company is currently burning cash at a rate that exceeds its operational cash generation, which necessitates reliance on external capital sources to sustain operations. All three margins reflect this financial reality: the gross margin is 0.0%, the operating margin is -587.5%, and the profit margin is 0.0%, suggesting that the company's cost of goods sold or operating expenses are either not yet realized in a way that generates gross profit or are disproportionately high relative to sales in the current reporting period. Regarding solvency, the company holds $256.02M in cash against $36.23M in debt, resulting in a debt-to-equity ratio of 118.22, which characterizes the balance sheet as highly leveraged despite the nominal debt amount, primarily due to the negative equity implied by the losses. The current ratio is 3.83, which indicates a strong position in short-term liquidity as current assets are more than three times current liabilities, providing a buffer against immediate financial obligations. Finally, the return on equity is -181.6% and the return on assets is -25.1%, metrics that reveal management effectiveness is currently measured by the preservation of capital rather than the generation of returns, as the negative percentages signify that the company's operations and asset base are currently eroding shareholder and creditor value.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed at -2.75, implying that the market expects a continued period of negative earnings or a significant turnaround before positive earnings are realized. The price-to-book ratio is 8.71, which indicates a substantial market premium over the company's book value, suggesting investors are pricing in significant future potential from the pipeline despite current financial losses. Alternative valuation metrics show a price-to-sales ratio of 12.69 and an EV/EBITDA of -0.32, suggesting that the company is valued primarily on its revenue potential and intangible assets rather than earnings power, a common practice for clinical-stage biotechs. The stock has traded within a range with a 52-week high of $3.40 and a 52-week low of $0.87, placing the current trading price in a volatile zone that reflects the high risk associated with clinical development outcomes. The beta value of 0.58 indicates that the stock's price volatility is significantly lower than the broader market, moving less than half as much as the overall market index, which may offer a hedge against general market fluctuations for risk-tolerant investors.
Growth & Income
The revenue growth year-over-year is -88.5%, while earnings growth is N/A, indicating a contraction in sales volume or a reclassification of revenue streams rather than organic expansion. The absence of positive earnings growth relative to revenue further implies that the company is in a phase of contraction or restructuring where top-line growth is not yet translating to bottom-line improvements, typical for firms scaling down operations or pivoting strategies. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning the entity reinvests all available capital, albeit negative, into its research pipeline and operational continuity rather than returning cash to shareholders. This growth and income profile summarizes a high-risk, high-potential asset class where income generation is nonexistent and growth is currently negative, reflecting the early-stage nature of the biotechnology development process.